ABSTRACT
Squamous cell carcinoma, in the clinical manifestation, is a form of cancer derived from lesions of keratinocytes of epidermis or accessories such as sebaceous ducts, hair follicles, sweat glands, etc. The disease is more common in older men, with prone locations at patients' scalp, face, neck and arms and other exposed parts. Head and neck squamous cell carcinoma [HNSCC] causes a serious impact on patients' daily life, making patients suffer from double blow in mental and physical aspects and reducing patients' life quality. To find effective treatment method for HNSCC, our hospital studies clinical effects of combination therapy of tegafur gimer, docetaxel and carboplatin for the disease. By way of grouping research, therapeutic effect of such treatment and adverse reactions were assessed and analyzed. The study clearly and fully confirms effectiveness of combination therapy of tegafur gimer, docetaxel and carboplatin for HNSCC
ABSTRACT
Objective:To investigate the effect of simvastatin on expression of pluripotent markers Oct3/4, Nanog, and Sox-2 in human breast cancer MCF-7 cells. Methods:Quantitative reverse transcription-polymerase chain reaction (qRT-PCR), immunofluo-rescent staining, flow cytometry, and Western blot were used to detect the expression of pluripotency markers Oct3/4, Nanog, and Sox-2 in human breast cancer MCF-7 cells treated with different doses of simvastatin. Results:qRT-PCR revealed the more signifi-cant inhibition of gene expressions of Oct3/4, Nanog, and Sox-2 in human breast cancer MCF-7 cells when subjected to high doses of simvastatin (10, 50, and 100 μmol/L) compared with the control group (P0.05). The inhibitory effect of simvastatin on the gene expressions of Oct3/4 and Nanog was more significantly apparent at 50 and 100 μmol/L dosages than at 10 μmol/L (P0.05). Between the two higher-dose treatments (50 and 100 μmol/L), no significant difference in the inhibitory expressions of Oct3/4, Nanog, and Sox-2 in MCF-7 cells was found. Meanwhile, in the 10 μmol/L simvastatin treatment, immunoflurescent staining showed a marked reduction in the protein expression of all three pluripotent markers in MCF-7 cells, and flow cytometry demonstrated a decrease of Oct3/4-, Nanog-, and Sox-2-positive cells (P<0.05). Western blot further revealed that the protein expression of Oct3/4, Nanog, and Sox-2 in MCF-7 cells was significantly declined by the same simvastatin dose (P<0.05). Conclusion: Simvastatin can inhibit the expression of pluripotent markers Oct3/4, Nanog, and Sox-2 in human breast cancer MCF-7 cells, proving the anti-cancer properties of simvastatin.